Chemomab Therapeutics (CMMB) Income from Continuing Operations (2017 - 2025)

Chemomab Therapeutics (CMMB) has 9 years of Income from Continuing Operations data on file, last reported at 625680763000.0 in Q4 2025.

• Quarterly Income from Continuing Operations rose 65.9% year-over-year to 625680763000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 1002818208000.0 (up 165.9% YoY) and the FY2025 annual result came in at 8995000.0, up 35.5% from the prior year.
• Income from Continuing Operations grew to 625680763000.0 in Q4 2025, from 1742000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 625680763000.0 in Q4 2025 to a low of 5104000.0 in Q1 2022.
• A 5-year average of 55714219777.78 and a median of 3749500.0 in 2024 frame the typical range for Income from Continuing Operations.
• Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 199.53% — and 2024, when it jumped 11036839.42%.
• Tracing CMMB's Income from Continuing Operations over 5 years: stood at 5036000.0 in 2021, then surged by 263.86% to 8252000.0 in 2022, then plunged by 58.59% to 3417000.0 in 2023, then jumped by 11036839.42% to 377132220000.0 in 2024, then soared by 65.9% to 625680763000.0 in 2025.
• The last three Income from Continuing Operations figures came in at 625680763000.0 (Q4 2025), 1742000.0 (Q3 2025), and 377132220000.0 (Q4 2024), per Business Quant data.